Nicotine Metabolism May Explain Ethnic Variations in Lung Cancer Rates

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 2
Volume 11
Issue 2

SAN FRANCISCO-Chinese-Americans take in significantly less nicotine per cigarette than whites and Latinos, allowing Chinese-American smokers to smoke fewer cigarettes than their ethnic counterparts to achieve the same nicotine-related

SAN FRANCISCO—Chinese-Americans take in significantly less nicotine per cigarette than whites and Latinos, allowing Chinese-American smokers to smoke fewer cigarettes than their ethnic counterparts to achieve the same nicotine-related effects, a new study suggests.

The Chinese-American smokers metabolized nicotine 35% more slowly than the white or Latino smokers in the study, and the rate of nicotine metabolism correlated significantly with nicotine intake from cigarette smoke.

These findings may explain why Chinese-Americans have a lower rate of lung cancer than other ethnic groups, concluded Neal L. Benowitz, MD, and his colleagues at the University of California at San Francisco (J Natl Cancer Inst 94:108-115, 2002).

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.